Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/109662
Title: The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS.
Author: Hernández Martinez Lapiscina, Elena
Fraga Pumar, Elena
Gabilondo, Iñigo
Martínez Heras, Eloy
Torres Torres, Ruben
Ortiz Pérez, Santiago
Llufriu Duran, Sara
Tercero, Ana
Andorra, Magi
Figueras Roca, Marc
Lampert, Erika
Zubizarreta, Irati
Saiz Hinajeros, Albert
Sánchez Dalmau, Bernardo
Villoslada, Pablo
Keywords: Esclerosi múltiple
Malalties neurodegeneratives
Visió
Depressió psíquica
Ansietat
Multiple sclerosis
Neurodegenerative Diseases
Visión
Mental depression
Anxiety
Issue Date: 15-Dec-2014
Publisher: BioMed Central
Abstract: BACKGROUND: Multiple Sclerosis (MS) is an immune-mediated disease of the Central Nervous System with two major underlying etiopathogenic processes: inflammation and neurodegeneration. The latter determines the prognosis of this disease. MS is the main cause of non-traumatic disability in middle-aged populations. FINDINGS: The MS-VisualPath Cohort was set up to study the neurodegenerative component of MS using advanced imaging techniques by focusing on analysis of the visual pathway in a middle-aged MS population in Barcelona, Spain. We started the recruitment of patients in the early phase of MS in 2010 and it remains permanently open. All patients undergo a complete neurological and ophthalmological examination including measurements of physical and disability (Expanded Disability Status Scale; Multiple Sclerosis Functional Composite and neuropsychological tests), disease activity (relapses) and visual function testing (visual acuity, color vision and visual field). The MS-VisualPath protocol also assesses the presence of anxiety and depressive symptoms (Hospital Anxiety and Depression Scale), general quality of life (SF-36) and visual quality of life (25-Item National Eye Institute Visual Function Questionnaire with the 10-Item Neuro-Ophthalmic Supplement). In addition, the imaging protocol includes both retinal (Optical Coherence Tomography and Wide-Field Fundus Imaging) and brain imaging (Magnetic Resonance Imaging). Finally, multifocal Visual Evoked Potentials are used to perform neurophysiological assessment of the visual pathway. DISCUSSION: The analysis of the visual pathway with advance imaging and electrophysilogical tools in parallel with clinical information will provide significant and new knowledge regarding neurodegeneration in MS and provide new clinical and imaging biomarkers to help monitor disease progression in these patients.
Note: Reproducció del document publicat a: https://doi.org/10.1186/1756-0500-7-910
It is part of: BMC Research notes, 2014, vol. 7, num. 910
Related resource: https://doi.org/10.1186/1756-0500-7-910
URI: http://hdl.handle.net/2445/109662
ISSN: 1756-0500
Appears in Collections:Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
668722.pdf463.78 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons